

Resource Summary Report

Generated by [nidm-terms](#) on Sep 23, 2026

University of Virginia School of Medicine Center for Human Therapeutics cGMP Core Facility

RRID:SCR_025475

Type: Tool

Proper Citation

University of Virginia School of Medicine Center for Human Therapeutics cGMP Core Facility (RRID:SCR_025475)

Resource Information

URL: <https://med.virginia.edu/center-for-human-therapeutics-cgmp-facility/>

Proper Citation: University of Virginia School of Medicine Center for Human Therapeutics cGMP Core Facility (RRID:SCR_025475)

Description: Offers manufacturing of cellular and biologics for safety and initial efficacy testing in first-in-human, pilot, and Phase I clinical trials. Facilitates bench-to-bed translation into novel cellular therapies. Provides focused scientific, technical, and regulatory support for investigator-initiated investigational new drug applications (INDs) in cell and gene therapy. Current and completed trials include hematologic malignancies multiple myeloma, breast cancer, prostate cancer, glioblastoma, neuroblastoma, and pancreatic cancer. The potential applications of cellular therapy and biologics are not limited to cancer, a large number of disease indications such as cardiovascular, autoimmune diseases, diabetes, neurological diseases, etc.

Synonyms: , UVA School of Medicine Center for Human Therapeutics cGMP Facility, University of Virginia School of Medicine Center for Human Therapeutics cGMP Facility

Resource Type: access service resource, core facility, service resource

Keywords: manufacturing of cellular and biologics, safety and initial efficacy testing, novel cellular therapies, new drug applications,

Resource Name: University of Virginia School of Medicine Center for Human Therapeutics cGMP Core Facility

Resource ID: SCR_025475

Alternate IDs: ABRF_2828

Alternate URLs: <https://coremarketplace.org/?FacilityID=2828&citation=1>

Record Creation Time: 20240712T053246+0000

Record Last Update: 20260919T200025+0000

Ratings and Alerts

No rating or validation information has been found for University of Virginia School of Medicine Center for Human Therapeutics cGMP Core Facility.

No alerts have been found for University of Virginia School of Medicine Center for Human Therapeutics cGMP Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Ninmer EK, et al. (2026) Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab). Cancer research communications, 6(4), 994.

Ninmer EK, et al. (2026) Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). Journal for immunotherapy of cancer, 14(3).

Horton WB, et al. (2026) Premeal insulin administration lowers postprandial blood glucose and increases myocardial microvascular blood flow in people with type 1 diabetes: a randomised, crossover clinical trial. Diabetologia.